Titan Medical to Report Year-End 2020 Financial Results and Host Webcast on February 22, 2021
Titan Medical Inc. (TMD, TMDI) is set to release its fourth quarter and year-end financial results on February 22, 2021, before market opening. A management-led investor audio webcast will follow at 4:30 PM ET to discuss these results.
The company specializes in developing robotic surgical technologies, particularly the Enos™ system, which focuses on gynecologic surgical applications. Previously, certain technologies have been licensed to Medtronic, retaining commercialization rights for the Enos system.
- Titan Medical is developing the Enos system, which includes advanced 3D and 2D vision systems.
- The company retains worldwide rights to commercialize technologies licensed to Medtronic.
- None.
Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announces that the Company plans to issue its fourth quarter and year-end financial results prior to market opening Monday, February 22, 2021 and management will host an investor audio webcast at 4:30 pm ET to discuss financial results and business highlights. Speakers will include David J. McNally, President and Chief Executive Officer, Monique L. Delorme, Chief Financial Officer, and Perry A. Genova, Ph.D., Senior Vice President, Research and Development.
A link to the live audio webcast will be made available on the "Investor Relations" section of the Company’s website, www.titanmedicalinc.com. A webcast replay will be archived and accessible on the Company’s website shortly after conclusion of the live audio webcast.
About Titan Medical
Titan Medical Inc., a medical device company headquartered in Toronto, is focused on developing robotic assisted technologies for application in single access surgery. The Enos™ system, by Titan Medical, is being developed with dual 3D and 2D high-definition vision systems, multi-articulating instruments, and an ergonomic surgeon workstation. With the Enos system, Titan intends to initially pursue gynecologic surgical indications.
Certain of Titan’s robotic assisted surgical technologies and related intellectual property have been licensed to Medtronic plc, while retaining world-wide rights to commercialize the technologies for use with the Enos system.
Enos™ is a trademark of Titan Medical Inc.
For more information, please visit www.titanmedicalinc.com.
Forward-Looking Statements
This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws. Such statements reflect the current expectations of management of the Company’s future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements, including, without limitation, references to: the Company’s focus on the design and development of surgical technologies for robotic single access surgery, that the Enos system is being developed with dual 3D and 2D high-definition vision systems, multi-articulating instruments and an ergonomic surgeon workstation and that Titan intends to initially pursue gynecologic surgical indications. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2019 (which may be viewed at www.sedar.com and at www.sec.gov). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, the Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210209005839/en/
FAQ
When will Titan Medical Inc. release its Q4 financial results?
What is Titan Medical's focus with the Enos system?
What time is the investor webcast for Titan Medical's financial results?
